NXY-059 for acute ischemic stroke: the promise of neuroprotection is finally realized?
Fisher
Marc
M
Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA. fisherm@ummhc.org
D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers; D017326:Clinical Trials, Phase III as Topic / Q000379:methods / Q000706:statistics & numerical data; D004311:Double-Blind Method; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D016166:Free Radical Scavengers / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D009589:Nitrogen Oxides / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D018401:Sample Size; D012720:Severity of Illness Index; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000009:adverse effects; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D001557:Benzenesulfonates; D015415:Biomarkers; D005343:Fibrinolytic Agents; D016166:Free Radical Scavengers; D018696:Neuroprotective Agents; D009589:Nitrogen Oxides; C120851:disufenton sodium; D010959:Tissue Plasminogen Activator